1379P Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations

C-MET alterations implicated as a negative prognostic factor. It can occur as exon 14 (METex14) skipping mutations, gene amplification, and protein overexpression. Vebreltinib (PLB-1001) is a potent highly selective c-MET inhibitor, which has shown promising results in pts with NGS-identified advanced METex14 skipping NSCLC in our previous phase I study. Here we present data from pts with METex14 mutation (Cohort 1) from a phase II, open-label, multicenter and multi-cohort KUNPENG study of PLB1001 conducted in locally advanced or metastatic NSCLC pts with c-MET alterations.